Skip to main navigation Skip to search Skip to main content

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients with High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial

Dickran Kazandjian*, Elizabeth Hill, Alexander Dew, Candis Morrison, Joseph Roswarski, Neha Korde, Michael Emanuel, Ani Petrosyan, Manisha Bhutani, Katherine R. Calvo, Alina Dulau-Florea, Mary Kwok, Min Jung Lee, Sunmin Lee, Liza Lindenberg, Sham Mailankody, Elisabet Manasanch, Irina Maric, Esther Mena, Nisha PatelNishant Tageja, Jane B. Trepel, Baris Turkbey, Hao Wei Wang, Weixin Wang, Constance Yuan, Yong Zhang, Raul Braylan, Peter Choyke, Maryalice Stetler-Stevenson, Seth M. Steinberg, William D. Figg, Mark Roschewski, Ola Landgren

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients with High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial'. Together they form a unique fingerprint.
Sort by

Medicine & Life Sciences